Antibodies News and Research

RSS

Researchers develop new technique to improve cancer treatments

An innovative technique to improve cancer treatments using tumour biopsies less than 30 minutes after they're taken has been developed at The University of Queensland.

25 Aug 2020

Study tracks the mutation rate of SARS-Cov-2 virus

Since COVID-19 began its menacing march across Wuhan, China, in December 2019, and then across the world, the SARS-CoV-2 virus has taken a "whatever works" strategy to ensure its replication and spread.

25 Aug 2020

Advances in Virus Epigenetics

Growing evidence shows viruses exploit epigenetic processes to control their life cycles but epigentic regulation of viral infections is not fully understood.

From Chromatrap® - Porvair Sciences Ltd 25 Aug 2020

Italy starts human trials of potential COVID-19 vaccine

Rome's Lazzaro Spallanzani Institute, a hospital specializing in infectious diseases will conduct trials on 90 volunteers in the coming weeks, joining a global effort to develop an immune response to the virus.

25 Aug 2020

COVID specific IgA monoclonal antibodies may provide effective immunity against coronavirus

A new study by researchers at MassBiologics of UMass Medical School published in Nature Communications suggests that COVID specific IgA monoclonal antibodies may provide effective immunity in the respiratory system against the novel coronavirus - a potentially critical feature of an effective vaccine.

25 Aug 2020

Scientists identify two markers of inflammation that predict severity of COVID-19 cases

Mount Sinai scientists have identified two markers of inflammation that reliably predict the severity of COVID-19 cases and likelihood of survival, providing a foundation for a diagnostic platform and therapeutic targets, according to a study published in Nature Medicine in August.

25 Aug 2020

UH to participate as study site for Pfizer and BioNTech's COVID-19 vaccine

University Hospitals announced today plans to participate as a study site for the Phase 2/3 global study sponsored by Pfizer Inc. and BioNTech SE of an investigational vaccine, BNT162b2, against SARS-CoV-2.

24 Aug 2020

Study reveals protective potential of all three major immunoglobulin isotypes against SARS-CoV-2

In a recent medRxiv preprint paper, researchers from Mount Sinai in New York showed that all three major immunoglobulin isotypes (IgM, IgG, and IgA) produced by our immune cells were capable of mediating neutralization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, neutralization titers correlated much better with binding levels of IgM and IgA1 than IgG.

24 Aug 2020

Ferrets not susceptible to SARS-CoV-2 infection

A recent study by scientists at the Cummings School of Veterinary Medicine at Tufts University has revealed that ferrets are not susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection even if they are directly exposed to symptomatic coronavirus disease 2019 (COVID-19) patients for a prolonged time.

24 Aug 2020

New cancer vaccine is predicted to be more effective in human trials

Jefferson researchers developing a cancer vaccine to prevent recurrences of gastric, pancreatic, esophageal and colon cancers have added a component that would make the vaccine more effective.

24 Aug 2020

Bioinsider presents ‘Therapeutic Pipeline for COVID-19’ virtual meeting on September 17, 2020

Bioinsider, has opened registration for its upcoming virtual meeting ‘Therapeutic Pipeline for COVID-19’ on September 17, 2020.

From Twist Bioscience 24 Aug 2020

FDA issues emergency use authorization for convalescent plasma in COVID-19

The FDA said that based on the scientific evidence available, it had released a decision memorandum that convalescent plasma may be useful in treating COVID-19 in hospitalized patients, and the known potential benefits of use outweigh the risks.

24 Aug 2020

Equine antibody preparation shows greater capacity to neutralize SARS-CoV-2 isolate than human convalescent plasma

A recent Brazilian study demonstrates that hyperimmune globulin formulations generated against the recombinant spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provide significantly high antibody titer with highly neutralizing capacity. The study is currently available on the bioRxiv preprint server.

23 Aug 2020

Pfizer/BioNTech COVID-19 vaccine candidate BNT162b2 profiled for large scale clinical trials

Although two RNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates elicited similar, dose-dependent neutralizing antibody titers in both younger and older adults, a recent study by researchers from the U.S. and Germany has shown that BNT162b2 is associated with less systemic reactogenicity in elderly individuals – supporting its selection for further phase 2/3 clinical trials. The study is currently available on medRxiv* preprint server.

23 Aug 2020

Raccoon dogs potential intermediate host for SARS-CoV-2

Researchers at the Friedrich Loeffler Institute in Germany have conducted a study demonstrating that raccoon dogs were a potential intermediate host in the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

23 Aug 2020

Nasal vaccine effective in preventing COVID-19 infection in mice

Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus.

21 Aug 2020

Researchers find clues to successful immune response in the T cells of COVID-19 patients

When news about a novel coronavirus switched from a chronicle of its progress in China to headlines about a worldwide COVID-19 pandemic, Gladstone Institutes scientist Nadia Roan, PhD, was in the midst of publishing several papers on T cells and their role in HIV spread and long-lasting infections.

21 Aug 2020

VUMC receives $34 million grant for nationwide convalescent plasma study

Vanderbilt University Medical Center has been awarded a one-year, $34-million grant by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, to conduct a nationwide study of "convalescent plasma" as a treatment for COVID-19.

21 Aug 2020

Macaques show low neutralizing antibody and cellular immune response to SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 presents a cynomolgus macaque model that develops symptomatic SARS-CoV-2 infection in a mild form, with low or no antibody responses, making it suitable to study human responses to vaccines and drugs targeting the virus.

21 Aug 2020

Study evaluates the reliability of new serological assays for detecting SARS-CoV-2 antibodies

Approximately four months after the initial description of cases of atypical pneumonia in Wuhan, China, in December 2019, COVID-19 had become a major pandemic threat.

20 Aug 2020

Antibodies News and Research

Researchers develop new technique to improve cancer treatments

Study tracks the mutation rate of SARS-Cov-2 virus

Advances in Virus Epigenetics

Italy starts human trials of potential COVID-19 vaccine

COVID specific IgA monoclonal antibodies may provide effective immunity against coronavirus

Scientists identify two markers of inflammation that predict severity of COVID-19 cases

UH to participate as study site for Pfizer and BioNTech's COVID-19 vaccine

Study reveals protective potential of all three major immunoglobulin isotypes against SARS-CoV-2

Ferrets not susceptible to SARS-CoV-2 infection

New cancer vaccine is predicted to be more effective in human trials

Bioinsider presents ‘Therapeutic Pipeline for COVID-19’ virtual meeting on September 17, 2020

FDA issues emergency use authorization for convalescent plasma in COVID-19

Equine antibody preparation shows greater capacity to neutralize SARS-CoV-2 isolate than human convalescent plasma

Pfizer/BioNTech COVID-19 vaccine candidate BNT162b2 profiled for large scale clinical trials

Raccoon dogs potential intermediate host for SARS-CoV-2

Nasal vaccine effective in preventing COVID-19 infection in mice

Researchers find clues to successful immune response in the T cells of COVID-19 patients

VUMC receives $34 million grant for nationwide convalescent plasma study

Macaques show low neutralizing antibody and cellular immune response to SARS-CoV-2

Study evaluates the reliability of new serological assays for detecting SARS-CoV-2 antibodies

Antibodies eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News